Dodge & Cox 13F: Cuts REGN Stake by $84M

Dodge & Cox recently trimmed its position in Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN) by 138,120 shares. This reduction leaves the fund with 4,458,238 shares valued at approximately $2.72 billion, according to the latest Form 13F filing with the SEC. The filing reflects holdings as of the end of the reporting period and may not indicate the fund's current position.

What Changed in Dodge & Cox's Regeneron Pharmaceuticals Position

Dodge & Cox reduced its stake in Regeneron by about 3%, cutting 138,120 shares from its previous holdings of 4,596,358 shares. The firm now holds 4,458,238 shares, valued at roughly $2.72 billion. This adjustment in their portfolio suggests a cautious approach despite maintaining a significant investment.

Regeneron Pharmaceuticals, Inc. Stock Down 23.3%

Shares of Regeneron Pharmaceuticals are trading around $610.79. The company has a market capitalization of $64.3 billion and a P/E ratio of 14.98, indicating a relatively moderate valuation compared to its earnings. With a forward P/E of 11.41, the stock may be seen as attractive for future growth. The stock's 52-week range spans from $503.25 to $821.11, with a 50-day moving average of $695.60 and a 200-day moving average of $696.34. Regeneron's beta of 0.238 suggests it is less volatile than the broader market.

Recent Earnings

Regeneron reported revenue of $14.92 billion, reflecting a growth rate of 19%. The company's earnings per share (EPS) stood at $40.97, with a net margin of 29.65% and a return on equity (ROE) of 14.55%. These figures underscore the company's strong financial performance. The next earnings report is expected on April 29, 2026.

Dividend

Regeneron offers an annual dividend rate of $3.76, yielding 0.61%. The dividend payout ratio is a conservative 8.74%, indicating the company retains a significant portion of its earnings for reinvestment or other purposes.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company based in Tarrytown, New York. It discovers, develops, manufactures, and commercializes medicines for a variety of diseases, including eye, allergic and inflammatory conditions, cardiovascular, metabolic, neurological, infectious, and rare diseases. The company is known for products like EYLEA, Dupixent, and Libtayo. Founded in 1988, Regeneron continues to innovate in the healthcare sector under the leadership of CEO Dr. Leonard S. Schleifer.

Bottom Line

Dodge & Cox's decision to trim its position in Regeneron Pharmaceuticals reflects a minor adjustment in its investment strategy. Investors often track such filings to gauge institutional sentiment toward a stock. It's important to remember that 13F filings are backward-looking and may not represent the fund's current stance.